Pharmaceuticals, Biotechnology and Life Sciences
An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of…
PRINCETON, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt; lt;a href="https://twitter.com/hashtag/BMS?src=hash" target="_blank"gt;#BMSlt;/agt;–Bristol-Myers Squibb Company (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial…
Top European VC leads 28-7’s Series A extension with $15 million and brings financing to over $80 million PARIS–(BUSINESS WIRE)–Sofinnova…
Transgene Combined General Meeting (ordinary and extraordinary sessions) ofTransgene’s shareholders will be held on May 22, 2019,
STRASBOURG, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Transgene?src=hash" target="_blank"gt;#Transgenelt;/agt;–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against…
DUBLIN–(BUSINESS WIRE)–The “Traveler’s Diarrhea – Market Insights, Epidemiology and Market Forecast – 2028” drug pipelines has been added to ResearchAndMarkets.com’s…
New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia Phase 1/2 Study for Merkel…
‒ Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS(1) of $0.14…
Gross margin (reported) improved 190 basis points to 53.0 percent of revenue Earnings per share (EPS) was $0.09 (reported), or…
DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy – Market Insights, Epidemiology and Market Forecast – 2028” drug pipelines has been added to…